Jeffrey L. Jorgensen

18.8k citations

197 papers · 8.2k indexed · h-index 46

Hematology top 0.2%
Oncology top 1%
Immunology top 0.5%
Public Health, Environmental and Occupational Health top 0.5%
Pathology and Forensic Medicine top 0.2%

Co-authors: Mark M. Davis L. Jeffrey Medeiros Hagop M. Kantarjian Farhad Ravandi Philip A. Reay Jörge E. Cortes Susan O’Brien Sa A. Wang
Topics: Lymphoma Diagnosis and Treatment (81 papers)Chronic Lymphocytic Leukemia Research (65 papers)Acute Lymphoblastic Leukemia research (56 papers)
Cited by: Hematology Genetics Pathology and Forensic Medicine
Journals: Nature The Lancet Journal of the American Chemical Society
Partner nations: United States China United Kingdom

In The Last Decade

Jeffrey L. Jorgensen

191 papers receiving 8.1k citations

Peers

Countries citing papers authored by Jeffrey L. Jorgensen

Since Specialization

Citations

This map shows the geographic impact of Jeffrey L. Jorgensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey L. Jorgensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey L. Jorgensen more than expected).

Fields of papers citing papers by Jeffrey L. Jorgensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey L. Jorgensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey L. Jorgensen. The network helps show where Jeffrey L. Jorgensen may publish in the future.

Co-authorship network of co-authors of Jeffrey L. Jorgensen

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey L. Jorgensen. A scholar is included among the top collaborators of Jeffrey L. Jorgensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey L. Jorgensen. Jeffrey L. Jorgensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia 2024 ·Leukemia & lymphoma ·(unknown),(unknown),Hagop M. Kantarjian,David McCue,Fadi Haddad,William G. Wierda,Alessandra Ferrajoli,Jan A. Burger,(unknown),Jeffrey L. Jorgensen,Sa A. Wang,Keyur Patel,Sanam Loghavi,Susan O’Brien,Farhad Ravandi	4
2	Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection 2023 ·Cytometry Part B Clinical Cytometry ·Sa A. Wang,Jeffrey L. Jorgensen,Shimin Hu,(unknown),Shaoying Li,Sanam Loghavi,Chi Young Ok,Beenu Thakral,Jie Xu,L. Jeffrey Medeiros,Wei Wang	10
3	Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD 2023 ·Leukemia ·Philip A. Thompson,Michael J. Keating,Alessandra Ferrajoli,Nitin Jain,Christine B. Peterson,Naveen Garg,Sa A. Wang,Jeffrey L. Jorgensen,Tapan M. Kadia,Prithviraj Bose,Naveen Pemmaraju,Nicholas J. Short,William G. Wierda	2
4	Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission 2023 ·Blood ·Elias Jabbour,Fadi Haddad,Nicholas J. Short,Jayastu Senapati,Nitin Jain,Koji Sasaki,Jeffrey L. Jorgensen,Sa A. Wang,Yesid Alvarado,Xuemei Wang,Courtney D. DiNardo,Lucia Masárová,Tapan M. Kadia,Rebecca Garris,Farhad Ravandi,Hagop M. Kantarjian	25
5	Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results 2023 ·American Journal of Hematology ·Hagop M. Kantarjian,Nicholas J. Short,Nitin Jain,Koji Sasaki,Xuelin Huang,Fadi Haddad,Issa F. Khouri,Courtney D. DiNardo,Naveen Pemmaraju,William G. Wierda,Guillermo Garcia‐Manero,Partow Kebriaei,Rebecca Garris,Sanam Loghavi,Jeffrey L. Jorgensen,Monica Kwari,Susan O’Brien,Farhad Ravandi,Elias Jabbour	45
6	Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10⁻⁴ and higher 2022 ·American Journal of Hematology ·Elias Jabbour,Nicholas J. Short,Nitin Jain,(unknown),Jeffrey L. Jorgensen,Sa Wang,Xuemei Wang,Maro Ohanian,Yesid Alvarado,Tapan M. Kadia,Koji Sasaki,Rebecca Garris,Guillermo Garcia‐Manero,Farhad Ravandi,Hagop M. Kantarjian	23
7	Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML 2021 ·Blood ·Sergej Konoplev,Guilin Tang,Xiaoqiong Wang,Wei Wang,Beenu Thakral,Jie Xu,Sherry Pierce,Jeffrey L. Jorgensen,Farhad Ravandi,Ghayas C. Issa,Olga Pozdnyakova,Sa A. Wang,Robert P. Hasserjian	1
8	Tumor infiltrating lymphocyte grade in Merkel cell carcinoma: relationships with clinical factors and independent prognostic value 2020 ·Acta Oncologica ·Mehran Yusuf,Jeremy Gaskins,(unknown),(unknown),(unknown),(unknown),Paul Tennant,Jeffrey L. Jorgensen,Jeffrey M. Bumpous,Neal Dunlap	7
9	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML 2020 ·Blood Advances ·Nicholas J. Short,Hind Rafei,Naval Daver,Hyunsoo Hwang,Jing Ning,Jeffrey L. Jorgensen,Tapan M. Kadia,Courtney D. DiNardo,Sa A. Wang,Elias Jabbour,Uday Popat,Betül Oran,Jörge E. Cortes,Marina Konopleva,Musa Yılmaz,Ghayas C. Issa,Hagop M. Kantarjian,Farhad Ravandi	22
10	Immune status and the efficacy of adjuvant radiotherapy for patients with localized Merkel cell carcinoma of the head and neck 2020 ·Clinical & Translational Oncology ·Mehran Yusuf,Jeremy Gaskins,(unknown),(unknown),(unknown),(unknown),Paul Tennant,Jeffrey L. Jorgensen,Jeffrey M. Bumpous,Neal Dunlap	1
11	Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes 2020 ·Blood ·Nicholas J. Short,Hagop M. Kantarjian,Keyur P. Patel,Steven M. Kornblau,Jeffrey L. Jorgensen,Sa A. Wang,Marina Konopleva,Nitin Jain,Partow Kebriaei,Musa Yılmaz,Ghayas C. Issa,Jairo Matthews,(unknown),Rebecca Garris,Farhad Ravandi,Elias Jabbour	5
12	Early detection of transformation to BPDCN in a patient with MDS 2018 ·Experimental Hematology and Oncology ·Kamal Chamoun,Sanam Loghavi,Naveen Pemmaraju,Marina Konopleva,Michael H. Kroll,(unknown),(unknown),Courtney D. DiNardo,Tapan M. Kadia,Jeffrey L. Jorgensen,Michael Andreeff,Shimin Hu,Christopher B. Benton	13
13	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study 2018 ·The Lancet Haematology ·Elias Jabbour,Nicholas J. Short,Farhad Ravandi,Xuelin Huang,Naval Daver,Courtney D. DiNardo,Marina Konopleva,Naveen Pemmaraju,William G. Wierda,Guillermo Garcia‐Manero,Koji Sasaki,Jörge E. Cortes,Rebecca Garris,Joseph D. Khoury,Jeffrey L. Jorgensen,Nitin Jain,Joie Alvarez,Susan O’Brien,Hagop M. Kantarjian	160
14	CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia 2017 ·Blood ·(unknown),Charlene A. Audette,Yelena Kovtun,Naval Daver,Sa A. Wang,Sherry Pierce,Sergej Konoplev,Jeffrey L. Jorgensen,Marina Konopleva,Patrick A. Zweidler‐McKay,Hagop M. Kantarjian,Elias Jabbour,Joseph D. Khoury	2
15	Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents 2016 ·Journal of Clinical Pathology ·Lanshan Huang,Guillermo Garcia‐Manero,Elias Jabbour,Maitrayee Goswami,Mark J. Routbort,L. Jeffrey Medeiros,Jeffrey L. Jorgensen,Sa A. Wang	7
16	Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC) 2016 ·Clinical Lymphoma Myeloma & Leukemia ·Courtney D. DiNardo,Sarah A. Bannon,Mark J. Routbort,Anna R. Franklin,Maureen E. Mork,Mary Armanios,Emily M. Mace,Jordan S. Orange,(unknown),Jane E. Churpek,Koichi Takahashi,Jeffrey L. Jorgensen,Guillermo Garcia‐Manero,Steve Kornblau,Alison A. Bertuch,Hannah Cheung,Kapil N. Bhalla,P. Andrew Futreal,Lucy A. Godley,Keyur P. Patel	66
17	Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients 2015 ·Human Pathology ·Mariko Yabe,L. Jeffrey Medeiros,Guilin Tang,Sa A. Wang,Keyur P. Patel,Mark J. Routbort,Govind Bhagat,Carlos E. Bueso‐Ramos,Jeffrey L. Jorgensen,Rajyalakshmi Luthra,Weina Chen,Tariq Muzzafar,Rashmi Kanagal‐Shamanna,Joseph D. Khoury,Yahya Daneshbod,Masoud Davanlou,Shaoying Li,Ken H. Young,Roberto N. Miranda	11
18	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response 2014 ·European Journal Of Haematology ·Qi Shen,Juan Ouyang,Guilin Tang,Elias Jabbour,Guillermo Garcia‐Manero,Mark J. Routbort,Sergej Konoplev,Carlos E. Bueso‐Ramos,L. Jeffrey Medeiros,Jeffrey L. Jorgensen,Sa A. Wang	24
19	Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China. 2010 ·Archives of Pathology & Laboratory Medicine ·Ting Li,L. Jeffrey Medeiros,Pei Lin,(unknown),(unknown),(unknown),Patrick A. Lennon,Peter Hu,Jeffrey L. Jorgensen,Mei Liang,Hua Guo,Changhong Yin	7
20	AIDS-Related Systemic Non-Hodgkin's Lymphoma at a Large Community Program 2002 ·AIDS Research and Human Retroviruses ·Regis A. Vilchez,Claudia A. Kozinetz,Jeffrey L. Jorgensen,Michael H. Kroll,Janet S. Butel	17

About Jeffrey L. Jorgensen

Jeffrey L. Jorgensen is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 197 papers that have together received 8.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (65 papers) and Acute Lymphoblastic Leukemia research (56 papers). The work is most often cited by research in Hematology (2.9k citations), Genetics (2.0k citations) and Pathology and Forensic Medicine (2.5k citations). Jeffrey L. Jorgensen has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Mark M. Davis, L. Jeffrey Medeiros, Hagop M. Kantarjian, Farhad Ravandi, Philip A. Reay, Jörge E. Cortes, Susan O’Brien, Sa A. Wang, Stefan Faderl and Deborah A. Thomas. Their work appears in journals such as Nature, The Lancet and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact